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34441
Keratoderma blenorrhagicum and balanitis circinata: Indicators
of reactive arthritis
Dayoung Ko, MD, Henry Ford Hospital, Department of Dermatology;
Meredith Hengy, BS, Wayne States University School of Medicine;
Chauncey McHargue, MD, Henry Ford Hospital, Department of Dermatology
A 25-year-old healthy man was admitted with a 3-month history of joint pains in his
feet and right knee, leading to difficulty ambulating. The patient had been previously
treated without a definitive diagnosis, with NSAIDs and systemic steroids, without
improvement. He also endorsed a 3-week history of an extensive, diffuse rash with
significant involvement of the palms, soles, and genitals. He denied involvement in
the oral mucosa or conjunctiva. Lesions were tender—the plantar lesions
contributing significantly to painful ambulation. The physical examination was
notable for hyperkeratotic scaly purpuric papules and plaques on the soles and
between the toes, hyperkeratotic ostraceous nodules on the arms, knees, trunk, and
soles, and erythematous scaly plaque on the groin involving the penis. Right fourth
finger PIP with swelling. Oral mucosa and conjunctiva were clear; nails were
normal. Labs were notable for leukocytosis and elevated inflammatory markers; the
urine was positive for chlamydia trachomatis, negative for gonorrhea and HIV,
syphilis, ANA, RF was negative while HLA-B27 positive. The diagnosis of reactive
arthritis was made and treatment with indomethacin, doxycycline, and prednisone
resulted in mild improvement during his hospitalization. This case represents the
classic presentation of reactive arthritis with keratoderma blenorrhagicum and
balanitis circinata with chlamydia trachomatis infection. Keratoderma blenorrhagicum is characteristic of reactive arthritis, although occurring in only 10% of patients.
In patients with palmoplantar keratoderma or otherwise typically appearing
psoriasis and psoriatic arthritis, it is important to consider the diagnosis of reactive
arthritis and expand the history and physical to elucidate the diagnosis.
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Laser hair removal treatment considerations for Ehlers Danlos
syndrome
Michael Abrouk, Harvard MGH Dermatology; Sandy Tsao, Harvard
MGH Dermatology
EDS is a clinically and genetically heterogenous group of heritable connective tissue
disorders involving a pathogenic disruption of collagen fibrils. Here we present a
case of laser hair removal in the setting of EDS (type 6a) in a 29-year-old female
phototype 2 patient successfully treated with 755-nm alexandrite laser for aesthetic
laser hair removal. Our patient was born with a dislocated hip and diagnosed at age 6
with EDS type 6a with genetic confirmation of PLOD1 positive gene mutation, poor
wound healing, chronic sacroiliac joint dysfunction, kyphoscoliosis and bilateral hip
dysplasia. She also had a myocardial infarction, right renal artery dissection and iliac
artery dissection. She was interested in aesthetic laser hair removal and noted a
significant scarring history with numerous hypopigmented scars throughout her
extremities with shaving leaving her with scarring on occasion. Given her complex
connective tissue disease history with significant morbidity particular consideration
was given to planning her laser hair removal treatment sessions for the bikini line.
Clinically our patient was phototype 2 with the bikini line containing dark brown
terminal hair. To clinically identify endpoints and mitigate potential complications
including scarring a test spot was initially performed. The test spot was performed
with the alexandrite laser 755 nm, fluence 16 J/cm2, 10-ms pulse duration, 18-mm
spot size, dynamic cooling device with 4 total pulses in separate areas. No
undesirable endpoints, pigmentary alteration, or scarring was observed and full
treatment sessions were initiated with 755-nm 16-18 J/cm2, 10-ms pulse duration,
18-mm spot size, dynamic cooling device with excellent clinical response.
Commercial Disclosure: None identified.
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Kombucha-induced irritant contact dermatitis
Catherine C. Motosko, MD, University of Miami, Department of
Dermatology, Miami, FL; Michael Abrouk, Mass General Dermatology
Laser & Cosmetic Center, Boston, MA
A 30-year-old woman presented with a 2-month history of an intermittent rash on the
bilateral upper cutaneous lip. Rash was originally thought to be early herpes
simplex, but was unresponsive to a 7-day course of valacyclovir. Patient noted the
rash to appear during periods of increased consumption of kombucha, a fermented
tea. She had only been applying petrolatum to the area. She had no history of atopy,
and no significant medical history. She worked in a hospital without any significant
occupational exposures. On the upper cutaneous lip there were 2 symmetrically
placed pink macules. The presumed diagnosis was an irritant contact allergy in
response to the increased consumption of kombucha. The patient was advised to
decrease consumption of kombucha, with resolution of the rash occurring within 1
week. Kombucha is a slightly sweet and acidic beverage made of fermented black tea
and a symbiotic culture of yeasts and bacteria. Believed to first have originated in
China, it has recently gained popularity due to its potential health benefits; however,
there remain a paucity of benefits reported in literature. To our knowledge, this is
the first report of a kombucha-induced irritant contact dermatitis, which is likely due
to the high pH (approximately 2.8) of the fermented tea. This case highlights the
importance of a thorough history in patients with suspected contact dermatitis with
emphasis on both topical products as well as herbal remedies.
Commercial Disclosure: None identified.
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Lenalidomide-induced pityriasiform eruption followed by
blaschkitis in a patient with multiple myeloma
Alexander Jafari, BA, Tulane University School of Medicine,
Department of Dermatology; Garrett Vick, MD, Tulane University
School of Medicine, Department of Dermatopathology; Laura Williams, MD,
Tulane Univeristy School of Medicine, Department of Dermatology
Lenalidomide is a thalidomide analog used in the treatment of hematologic
malignancies such as multiple myeloma (MM). We present a previously undescribed
pityriasiform eruption due to lenalidomide followed by a secondary eruption
suggestive of blaschkitis. A 76-year-old Chinese man with MM presented to the
dermatology clinic with a progressive, pruritic eruption on the chest and axillae
bilaterally for 1 year. The eruption emerged 2 weeks after receiving lenalidomide
following an autologous stem cell transplantation for MM. On examination, the
patient had erythematous, hyperpigmented scaly papules and plaques on the lateral
chest and axillae bilaterally. A skin biopsy demonstrated lichenoid and perivascular
lymphocytic infiltrate with scattered eosinophils, neutrophils, and extravasated
erythrocytes, consistent with a pityriasiform eruption. The patient discontinued
lenalidomide and started a topical over-the-counter corticosteroid for 2 weeks. The
patient noted marked improvement in the eruption and associated pruritus. After a
drug holiday of 2 months, the patient resumed lenalidomide. Five days later, a
pruritic eruption appeared involving the bilateral axillae and left lower abdomen
circling around to the left lower back. On examination, erythematous macules and
papules were noted to coalesce over a salmon-colored base along the lines of
Blaschko, extending from the left lower abdominal quadrant, crossing the left flank
and continuing to the left lower back without crossing the midline. The patient was
recommended to treat through this eruption and was instructed to apply a topical
corticosteroid cream and resume lenalidomide. A month later, the patient reported
that the eruption and associated pruritus resolved with the aforementioned.
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